Dr. Joanne M. Donovan M.D. Ph.D. serves as Chief Medical Officer of the Company. Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine. From 1998 to July 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women's Hospital.
As the Chief Medical Officer of Astria Therapeutics Inc, the total compensation of Joanne Donovan at Astria Therapeutics Inc is $713,710. There are 1 executives at Astria Therapeutics Inc getting paid more, with Jill Milne having the highest compensation of $1,032,800.
Joanne Donovan is 63, he's been the Chief Medical Officer of Astria Therapeutics Inc since 2011. There are 3 older and 7 younger executives at Astria Therapeutics Inc. The oldest executive at Astria Therapeutics Inc is Michael Kishbauch, 71, who is the Independent Director.
Joanne's mailing address filed with the SEC is 1 Kendall Square B14202, Cambridge, MA 02139, USA.
Over the last 9 years, insiders at Astria Therapeutics Inc have traded over $0 worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth $36,777,564 . The most active insiders traders include Jean George, Nicholas Galakatos et Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of $2,617,339. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth $4,520,340.
Astria Therapeutics Inc executives and other stock owners filed with the SEC include: